Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults (FORM-Resp)

11 de novembro de 2026 atualizado por: First Affiliated Hospital of Ningbo University

Prospective Self-Control Study on the Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults

Formaldehyde exposure is common in some occupational environments, including anatomy laboratories, and may affect respiratory health. However, the early biological changes caused by short-term high-concentration formaldehyde exposure remain unclear.

This prospective self-controlled observational study aims to evaluate the effects of short-term high-concentration formaldehyde exposure on respiratory microecology, inflammatory biomarkers, and acute respiratory symptoms in healthy adults. Participants will be monitored before and after formaldehyde exposure, and changes in airway-related biological indicators will be assessed through biological samples and clinical evaluations.

The findings of this study may provide human evidence for exposure control, ventilation improvement, protective measures, and health risk assessment in environments with formaldehyde exposure.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This is a prospective self-controlled observational study designed to investigate early respiratory biological responses associated with short-term high-concentration formaldehyde exposure in healthy adults.

Participants will be healthy medical students who enter an anatomy laboratory and experience short-term formaldehyde exposure during anatomy training. Each participant will serve as his or her own control. Biological samples and clinical information will be collected at multiple time points, including before exposure (T0), 6 hours after exposure (T1), and 24 hours after exposure (T2).

The study will evaluate changes in respiratory microecological composition, local inflammatory responses, systemic inflammatory and oxidative stress-related biomarkers, and acute irritation symptoms after formaldehyde exposure. Formaldehyde exposure levels, exposure duration, and protective measures will also be recorded to explore the relationship between exposure intensity and biological responses.

At T0, baseline information, respiratory symptoms, induced sputum samples, peripheral blood samples, and other relevant assessments will be collected. During and after exposure, environmental formaldehyde concentrations and exposure-related information will be monitored. At T1 and T2, repeated assessments will be performed, including symptom evaluation, induced sputum collection, peripheral blood collection, inflammatory biomarker detection, and respiratory microecological analysis.

This study aims to provide human-based evidence regarding early respiratory effects of short-term formaldehyde exposure and may contribute to improving ventilation strategies, occupational protection measures, exposure duration control, and health risk assessment in formaldehyde-exposed environments.

Tipo de estudo

Observacional

Inscrição (Estimado)

65

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Zhejiang
      • Ningbo, Zhejiang, China, 315211
        • Wang Changlai Building, East Campus, Ningbo University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 35 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Healthy adult medical students who attend anatomy laboratory courses involving short-term formaldehyde exposure will be recruited. Participants will undergo prospective self-controlled observation before and after exposure. Changes in respiratory microbiome composition, airway inflammatory biomarkers, systemic inflammatory and oxidative stress indicators, and acute irritation symptoms after formaldehyde exposure will be evaluated.

Descrição

Inclusion Criteria:

  • 1: Aged 18-35 years old

    2: The healthy medical students who participated in the anatomy course for the first time had no systematic formaldehyde / formalin occupational or teaching exposure in the past 6 months.

    3: Health examination, and no history of chronic respiratory diseases ( such as asthma, active allergic rhinitis, chronic sinusitis, bronchiectasis, interstitial pulmonary fibrosis, etc. )

    4: There were no acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms in the past 4 weeks.

    5: There was no use of antibiotics, glucocorticoids, bronchodilators, and immunomodulatory drugs in the past 4 weeks.

    6: There was no obvious eye, nose, throat irritation or lower respiratory symptoms at baseline, and was able to cooperate with the completion of three induced sputum, two peripheral blood collections and related follow-up evaluations

    7: Voluntary to participate in and sign a written informed consent.

Exclusion Criteria:

  • 1: Have asthma, COPD, bronchiectasis, interstitial lung disease, chronic sinusitis, active allergic rhinitis or other chronic airway inflammatory diseases

    2: Acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms, or active allergies / obvious seasonal allergies occurred in the past 4 weeks

    3: Used antibiotics, systemic or inhaled corticosteroids, bronchodilators, immunomodulatory drugs in the past 4 weeks

    4: Current smoking, use of e-cigarettes or hookah, smoking history in the past six months, or obvious high exposure to second-hand smoke in the past four weeks

    5: Exposure to non-daily formaldehyde, formalin or other strong irritant chemicals in the past 4 weeks

    6: Have a clear history of allergy to formaldehyde or other chemicals, or intolerance to hypertonic saline atomization

    7: Pregnant or lactating women

    8: Severe cardiovascular and cerebrovascular diseases, coagulation dysfunction, recent hemoptysis, severe hypertension, recent ophthalmic surgery, epilepsy requiring drug treatment, severe arrhythmia or other conditions not suitable for induced sputum operation

    9: All follow-ups and biological sample collections could not be completed for personal reasons, or researchers considered it inappropriate to continue participating in the study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: RETROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Formaldehyde Exposure Cohort

Healthy adults receiving anatomy laboratory courses were enrolled in this prospective self-controlled observational study. Participants were exposed to short-term formaldehyde released from fixed tissue specimens in the anatomy laboratory and were evaluated before and after exposure.

Short-term high-concentration formaldehyde exposure during anatomy laboratory courses

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in the Shannon Diversity Index of Induced Sputum Microbiota
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The Shannon Diversity Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index evaluates microbial alpha diversity by accounting for both taxon richness and evenness. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater microbial diversity. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in the Chao1 Richness Index of Induced Sputum Microbiota
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The Chao1 Richness Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index estimates the number of microbial taxa in a sample. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater estimated microbial richness. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
R-Squared Value From Permutational Multivariate Analysis of Variance of Induced Sputum Microbial Community Structure Across Sampling Time Points
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Beta diversity of induced sputum microbiota will be evaluated using principal coordinates analysis and permutational multivariate analysis of variance. The primary reported measure will be the R-squared value from the permutational multivariate analysis of variance, representing the proportion of variation in microbial community structure explained by sampling time. Values range from 0 to 1, with higher values indicating that sampling time explains a greater proportion of variation in microbial community structure.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Induced Sputum Neutrophil Percentage
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage and reported in percentage points.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Neutrophils in Induced Sputum
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Macrophages and Monocytes in Induced Sputum
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of macrophages and monocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of macrophages and monocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Lymphocytes in Induced Sputum
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of lymphocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of lymphocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Eosinophils in Induced Sputum
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of eosinophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of eosinophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Bronchial Epithelial Cells in Induced Sputum
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of bronchial epithelial cells in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of bronchial epithelial cells. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 1 Beta Concentration in Induced Sputum Supernatant
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 1 beta concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 6 Concentration in Induced Sputum Supernatant
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 6 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 8 Concentration in Induced Sputum Supernatant
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 8 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Induced Sputum Supernatant
Prazo: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Tumor necrosis factor alpha concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in C-Reactive Protein Concentration in Peripheral Blood
Prazo: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

C-reactive protein concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 6 Concentration in Peripheral Blood
Prazo: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Interleukin 6 concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Peripheral Blood
Prazo: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Tumor necrosis factor alpha concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Malondialdehyde Concentration in Peripheral Blood
Prazo: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Malondialdehyde concentration will be measured in peripheral blood as a marker of oxidative stress. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Eye Irritation Score Assessed Using a Visual Analog Scale
Prazo: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Eye irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Nasal Irritation Score Assessed Using a Visual Analog Scale
Prazo: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Nasal irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Throat Irritation Score Assessed Using a Visual Analog Scale
Prazo: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Throat irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Cough Score Assessed Using a Visual Analog Scale
Prazo: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Cough will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Chest Tightness Score Assessed Using a Visual Analog Scale
Prazo: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Chest tightness will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Chao Cao, Ningbo University Affiliated First Hospital

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de outubro de 2026

Conclusão Primária (Real)

1 de novembro de 2026

Conclusão do estudo (Estimado)

30 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

14 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 2026-R311-01

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

The plan for sharing individual participant data (IPD) has not yet been determined. Any future data sharing will be considered in accordance with ethical requirements, participant privacy protection, and institutional policies.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever